Clinical trial · no report yet · Phase 2
Indi-Blade
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
- NCT05200988 ↗
- Active, not recruiting
- The Netherlands Cancer Institute
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| Podcasts | 6 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Clinical Study to Assess Efficacy of Induction Ipilimumab/Nivolumab to Spare the Bladder in Urothelial Bladder Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Urothelial Carcinoma; Bladder Cancer
- Interventions
- Ipilimumab + nivolumab
- Arms
- Induction with heckpoint inhibition followed by consolidative chemoradiation · Experimental
- Enrollment
- 50 (estimated)
- Primary outcomes
- Efficacy defined as bladder-intact event-free survival (BI-EFS)
- Sponsor
- The Netherlands Cancer Institute with Bristol-Myers Squibb
- Start
- Mar 14, 2022
- Primary completion
- Sep 5, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05200988 · updated Mar 18, 2024
Publications
linked from the registry- Mellema JJ, Stockem CF, Herberts C, Cheung SK, Vis DJ, van Rhijn BWG, Mertens LS, Boellaard TN, van Montfoort ML, Balduzzi S, de Feijter JM, van der Mijn JCK, Sharma S, El Naggar AC, Boormans JL, Franckena M, Meijer RP, Noteboom JL, Schaake EE, Robbrecht DGJ, Suelmann BBM, van der Heijden MS. Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2026 Apr;32(4):1241-1248. doi: 10.1038/s41591-026-04271-3. Epub 2026 Feb 27. PubMed 41760951
- Stockem CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, van Montfoort ML, Balduzzi S, Boormans JL, Franckena M, Meijer RP, Robbrecht DGJ, Suelmann BBM, Schaake EE, van der Heijden MS. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial. Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023. PubMed 37711193